Related Experiment Videos
A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients
Psychiatry Research
|February 1, 1981
Abstract:
Platelet monoamine oxidase activity (MAO) was studied serially over time in 16 chronic schizophrenic patients when medication free and then when medicated. Thirteen of the 16 patients had significant decreases in platelet MAO activity following neuroleptic drug treatment. The change in MAO activity was found to be correlated with response to treatment and to dose of medication.
Insights
Neuroleptic drug treatment significantly decreased platelet monoamine oxidase (MAO) activity in most chronic schizophrenic patients. This reduction in MAO activity correlated with treatment response and medication dosage.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a complex psychiatric disorder.
- Platelet monoamine oxidase (MAO) is an enzyme implicated in neurotransmitter metabolism.
- Understanding MAO activity in schizophrenia may offer therapeutic insights.
Purpose of the Study:
- To investigate serial changes in platelet monoamine oxidase (MAO) activity in chronic schizophrenic patients.
- To determine the effect of neuroleptic drug treatment on platelet MAO activity.
- To explore the relationship between MAO activity changes and treatment response.
Main Methods:
- Serial measurements of platelet monoamine oxidase (MAO) activity were conducted.
- 16 chronic schizophrenic patients were studied.
- Patients were assessed both when medication-free and during neuroleptic drug treatment.
Main Results:
- Platelet MAO activity significantly decreased in 13 out of 16 patients after neuroleptic treatment.
- The observed changes in MAO activity were correlated with the patients' clinical response to treatment.
- A correlation was also found between MAO activity changes and the prescribed dose of medication.
Conclusions:
- Neuroleptic drug treatment can significantly reduce platelet monoamine oxidase (MAO) activity in chronic schizophrenic patients.
- Platelet MAO activity may serve as a potential biomarker for treatment response in schizophrenia.
- The findings suggest a link between MAO enzyme function and the efficacy of antipsychotic medications.